At a time of rapid growth in the consumer genetics space, PerkinElmer and NorthShore are developing digital apps to ease access to genetic disease risk information through Helix.
PerkinElmer is working on an app that reports pathogenic or likely pathogenic ACMG-59 genetic variants, and NorthShore's app will report a prostate cancer risk score.
The effort, sponsored by two therapeutics companies, is providing no-cost genetic testing and counseling for people with Duchenne who otherwise couldn't afford it.
The company plans to use the proceeds to repay loan and revolving credit facilities incurred to pay a portion of its 2017 acquisition of Euroimmun.
The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.
The company said PerkinElmer will pay A$.28 per share for its 89.9 million outstanding shares, a 100 percent premium to RHS's Feb. 23 closing price on the ASX.
If recommended by the US Department of Health and Human Services, spinal muscular atrophy screening will potentially be adopted on the state level.
Revenues in PerkinElmer's diagnostics business rose 23 percent in Q4, thanks largely to its acquisition of autoimmune diagnostic testing firm Euroimmun.
Among the firms reporting, BGI talked about plans to cut down the time and cost of its WGS service, and Invitae's CEO made a surprising proclamation about genetic testing.
The partners will use whole-genome sequencing to investigate the molecular pathways involved in GNE myopathy, a progressive muscle-wasting disease.
The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.
Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.